The influence of hormone therapies on colon and rectal cancer

European Journal of Epidemiology

Volumn 31, Issue 5, 2016, Pages 481-489

  Mørch, Lina Steinrud ^a,b   Lidegaard, Øjvind ^a   Keiding, Niels ^c   Løkkegaard, Ellen ^c   Kjær, Susanne Krüger ^a,b  

^a Rigshospitalet   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Colon cancer; Hormone replacement therapy; Rectum cancer; Stage of disease; Types of hormone therapy

Indexed keywords

ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE; NORETHISTERONE; TIBOLONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER REGISTRY; COHORT ANALYSIS; COLON CANCER; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; RECTUM CANCER; RISK FACTOR; TREATMENT INDICATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DENMARK; HEALTH SURVEY; INCIDENCE; LONGITUDINAL STUDY; POSTMENOPAUSE; RECTAL NEOPLASMS; REGISTER; RISK ASSESSMENT;

AGED; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DENMARK; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MIDDLE AGED; POPULATION SURVEILLANCE; POSTMENOPAUSE; RECTAL NEOPLASMS; REGISTRIES; RISK ASSESSMENT;

EID: 84954317407     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-016-0116-z     Document Type: Article

References (38)

1. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574–82.
2. Nanda K, Bastian LA, Hasselblad V, et al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol. 1999;93:880–8.
3. Lin KJ, Cheung WY, Lai JY, et al. The effect of estrogen vs. combined estrogen-progestin therapy on the risk of colorectal cancer. Int J Cancer. 2012;130:419–30.
4. Tsilidis KK, Allen NE, Key TJ, et al. Menopausal hormone therapy and risk of colorectal cancer in the European prospective investigation into cancer and nutrition. Int J Cancer. 2011;128:1881–9.
5. Hoffmeister M, Raum E, Krtschil A, Chang-Claude J, Brenner H. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. Clin Pharmacol Ther. 2009;86:416–24.
6. Dinger JC, Heinemann LA, Mohner S, Thai MD, Assmann A. Colon cancer risk and different HRT formulations: a case–control study. BMC Cancer. 2007;7:76.
7. Johnson JR, Lacey JV Jr, Lazovich D, Geller MA, Schairer C, Schatzkin A, Flood A. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:196–203.
8. Csizmadi I, Collet JP, Benedetti A, et al. The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women. Br J Cancer. 2004;90:76–81.
9. Corrao G, Zambon A, Conti V, Nicotra F, La Vecchia C, Fornari C, Cesana G, Contiero P, Tagliabue G, Nappi RE, Merlino L. Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol. 2008;19:150–5.
10. Morois S, Fournier A, Clavel-Chapelon F, Mesrine S, Boutron-Ruault MC. Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3 N prospective cohort: True associations or bias? Eur J Epidemiol. 2012;27:439–52.
11. Cummings SR, Ettinger B, Delmas PD, et al. LIFT trial investigators. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697–708.
12. Hildebrand JS, Jacobs EJ, Campbell PT, et al. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev. 2009;18:2835–41.
13. Delellis Henderson K, Duan L, Sullivan-Halley J, Ma H, Clarke CA, Neuhausen SL, Templeman C, Bernstein L. Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiol. 2010;171(4):415–25.
14. Wu AH, Siegmund KD, Long TI, Cozen W, Wan P, Tseng CC, Shibata D, Laird PW. Hormone therapy. DNA methylation and colon cancer. Carcinogenesis. 2010;31:1060–7.
15. Gervaz P, Bouzourene H, Cerottini JP, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum. 2001;44:364–72.
16. Li M, Li JY, Zhao AL, et al. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. Oncology. 2007;73:52–7.
17. Simon MS, Chlebowski RT, Wactawski-Wende J, et al. Estrogen plus Progestin and colorectal cancer incidence and mortality. J Clin Oncol. 2012;30:3983–90.
18. Nielsen LH, Løkkegaard E, Andreasen AH, et al. Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf. 2008;17:384–8.
19. Mørch LS, Løkkegaard E, Andreasen AH, et al. Hormone therapy and ovarian cancer. JAMA. 2009;302:298–305.
20. Løkkegaard E, Lidegaard O, Møller LN, et al. Hormone replacement therapy in Denmark, 1995–2004. Acta Obstet Gynecol Scand. 2007;86:1342–51.
21. Tutton PJ, Barkla DH. Steroid hormones as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells. Anticancer Res. 1988;8:451–6.
22. Lointier P, Wildrick DM, Boman BM. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res. 1992;12:1327–30.
23. Singh S, Paraskeva C, Gallimore PH, et al. Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res. 1994;14:1037–41.
24. Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7:536–40.
25. Murphy N, Strickler HD, Stanczyk FZ, Xue X, Wassertheil-Smoller S, Rohan TE, Ho GY, Anderson GL, Potter JD, Gunter MJ. A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women. J Natl Cancer Inst. 2015;107. doi:10.1093/jnci/djv210.
26. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Women’s Health Initiative Investigators. Estrogen plus Progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991–1004.
27. Long MD, Martin CF, Galanko JA, et al. Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: a population-based case-control study. Am J Gastroenterol. 2010;105:1843–50.
28. Brändstedt J, Wangefjord S, Nodin B, Eberhard J, Jirström K, Manjer J. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability. BMC Cancer. 2014;14:371.
29. Arem H, Park Y, Felix AS, Zervoudakis A, Brinton LA, Matthews CE, Gunter MJ. Reproductive and hormonal factors and mortality among women with colorectal cancer in the NIH-AARP Diet and Health Study. Br J Cancer. 2015;113:562–8.
30. Storm HH. Completeness of cancer registration in Denmark 1943-1966 and efficacy of record linkage procedures. Int J Epidemiol. 1988;17:44–9.
31. Storm HH, Michelsen EV, Clemmesen IH, Pihl J. The Danish cancer register- history, content, quality, and use. Dan Med Bull. 1997;44:535–9.
32. Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish cancer register. A study based on clinical records from one county in Denmark. Eur J Cancer Prev. 2002;11:359–64.
33. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998;128:705–12.
34. Beral V. Million Women Study collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–27.
35. Mørch LS, Løkkegaard E, Andreasen AH, Kjaer SK, Lidegaard O. Hormone therapy and different ovarian cancers: a national cohort study. Am J Epidemiol. 2012;175:1234–42.
36. Mørch LS, Kjaer SK, Keiding N, Løkkegaard E, Lidegaard Ø. The influence of hormone therapies on type I and II endometrial cancer: a nationwide cohort study. Int J Cancer. 2015. doi:10.1002/ijc.29878. [Epub ahead of print].
37. Rossouw JE, Anderson GL, Prentice RL, Lacroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. J Am Med Assoc. 2002;288:321–33.
38. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. J Am Med Assoc. 2003;289:2673–84.